RecruitingPhase 2NCT07033481
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Studying Primary progressive aphasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EIP Pharma Inc
- Intervention
- Neflamapimod(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 40-85 years · All sexes
- Timeline
- 2025 – 2026
Study locations (3)
- Mayo Clinic, Rochester, Minnesota, United States
- The Ohio State University, Columbus, Ohio, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
CervoMed, Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07033481 on ClinicalTrials.govOther trials for Primary progressive aphasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07219680Intervention for Communication Quality of Life in Primary Progressive AphasiaUniversity of Texas at Austin
- RECRUITINGNANCT07260253Remotely-supervised Neuromodulation in PPAUniversity of Texas at Austin
- RECRUITINGNANCT07158216Long Term Effect of Brain Stimulation in PPAHospital San Carlos, Madrid
- RECRUITINGNCT06739967Speech and Language Interventions for Italian People With PPAIstituti Clinici Scientifici Maugeri SpA
- RECRUITINGPHASE2NCT06191198Communication Bridge 3 StudyUniversity of Chicago
- ACTIVE NOT RECRUITINGNANCT06211374Communication Bridge Pilot StudyUniversity of Chicago
- RECRUITINGPHASE2NCT05386394Transcranial Direct Current Stimulation in the Treatment of Primary Progressive AphasiaJohns Hopkins University
- ENROLLING BY INVITATIONNANCT05901233Speech-Language Treatment With Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive AphasiaUniversity of Texas at Austin